PCVX
Vaxcyte, Inc.
$58.71
-1.96 (-3.23%)
At close · Jul 8
Market Cap
$8.64B
Shares
144,397,682
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$58.71
Open$60.01
Day$56.97–60.40
52W$29.08–65.00
Avg vol 30d1.7M
Short int14.6M · 10.1% float · 10.7d
Short vol40%
Last earningsMay 6, 2026
DataJun 2020–Jul 2026
Filing10-Q · May 6
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bearish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+16%
above
Price vs 50-day avg
+12%
above
RSI (14)
62
neutral
MACD trend
Positive
52-week position
82%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+27%
trailing
6-month return
+28%
trailing
YTD return
+27%
this year
Relative strength
+20%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $53 › 200d $51 — 50d above 200d
Institutional flow
Distributing
7 of 338 funds reported for Jun 30 · net -1.1M sh shares
Insider flow
Distributing
Net -$239.3K over 90 days · 100% sells
Short interest
Rising
10.13% of float · ▲ +1.1% MoM · 10.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
338 holders — near 3-yr high, broad support
Squeeze score
82
high risk · 0–100
Fundamentals
EPS growth
−48%
Y/Y
Free cash flow
$-669.3M
Balance sheet
$174.0M
net cash
Quant / Vol
risk profile
Volatility
47%
annualized · 1-yr
Max drawdown
−28%
past year
ATR
4.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 5, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+16%
Bullish
Price vs 50-day avg
+12%
Bullish
RSI (14)
62
Neutral
MACD trend
Positive
Bullish
52-week position
82%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $53 › 200d $51 — 50d above 200d
Institutional flow
Distributing
7 of 338 funds reported for Jun 30 · net -1.1M sh shares
Insider flow
Distributing
Net -$239.3K over 90 days · 100% sells
Short interest
Rising
10.13% of float · ▲ +1.1% MoM · 10.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
338 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $29
Now $59 · 82%
52-wk high $65
vs 200-day avg +16%
vs 50-day avg +12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PCVX
this stock
Vaxcyte, Inc.
|
$8.64B | +27.2% | — | — | 10.1% |
|
ONC
BeOne Medicines Ltd.
|
$437.67B | -0.6% | +22179.2% | 890.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.01B | +9.9% | +46.2% | 29.5 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.03B | -14.0% | +20.8% | 16.3 | 3.2% |
|
ARGX
Argenx SE
|
$56.84B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PCVX | +1.0% | +26.7% | +27.6% | +1.0% | +27.2% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +1.2% | +25.9% | +20.1% | +1.2% | +17.9% |